Compositions and methods for treatment and detection of cancers

• US 9,975,965 B2
• Filed: 01/30/2016
• Issued: 05/22/2018
• Est. Priority Date: 01/16/2015
• Status: Active Grant

• Current Assignee: Academia Sinica (Government of The Republic of China)
• Original Assignee: Academia Sinica (Government of The Republic of China)
• Inventors: Wong, Chi-Huey, Hsu, Tsui-Ling, Lou, Yi-Wei, Lin, Chih-Wei, Yeh, Shih-Chi, Wu, Chung-Yi, Wu, Han-Chung
• Primary Examiner(s): BRISTOL, LYNN ANNE
• Application Number:
  US15/011,543
• Publication Number:
  US 20160289340A1
• Time in Patent Office: 843 Days
• Field of Search: 4241331
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/3053 Skin, nerves, brain
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57407 Specifically defined cancers

Abstract

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

Claims

1. An isolated monoclonal antibody or a binding fragment thereof, that specifically binds to Neu5Acα

2→

3Galβ

1→

3GalNAcβ

1→

3Galα

1→

4Galβ

1→

4Glcβ

1, wherein the antibody or the binding fragment thereof comprises a VH sequence having SEQ ID NO;

202, SEQ ID NO. 212, or SEQ ID NO;

222 and a VL sequence having SEQ ID NO;

203, SEQ ID NO. 213 or SEQ ID NO;

223.

2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a H-CDR1 sequence, a H-CDR2 sequence, and a H-CDR3 sequence wherein:

(i) H-CDR1 sequence is selected from SEQ ID NO;

207, SEQ ID NO;

217 and SEQ ID NO;

227;

(ii) H-CDR2 sequence is selected from SEQ ID NO;

208, SEQ ID NO;

218, and SEQ ID NO;

228; and

(iii) H-CDR3 sequence is selected from SEQ ID NO;

209, SEQ ID NO;

219 and SEQ ID NO;

229;

and comprising a L-CDR1 sequence, a L-CDR2 sequence and a L-CDR3 sequence wherein;

(iv) L-CDR1 sequence is selected from SEQ ID NO;

204, SEQ ID NO;

214, and SEQ ID NO;

224;

(v) L-CDR2 sequence is selected from SEQ ID NO;

205, SEQ ID NO;

215 and SEQ ID NO;

225; and

(vi) L-CDR3 sequence is selected from SEQ ID NO;

206, SEQ ID NO;

216 and SEQ ID NO;

226.

3. The isolated monoclonal antibody of claim 1, wherein the antibody is a humanized antibody.

4. The isolated monoclonal antibody of claim 2, wherein the antibody is a humanized antibody.

5. The isolated monoclonal antibody of claim 1 or 2, wherein the antibody is a chimeric antibody.

6. A pharmaceutical composition comprising the isolated monoclonal antibody or binding fragment thereof of claim 1 or 2 and a pharmaceutically acceptable carrier.